Date: 23rd November-2025

INNOVATIVE TREATMENT APPROACHES IN ONCOLOGICAL DISEASES: IMMUNOTHERAPY AND GENETIC MODIFICATION

Abduxalikova Diyoraxon
Teacher of public health technical college named after Republic No. 1 Abu Ali Ibn Sina

Annotation: This article analyzes innovative treatment approaches in oncological diseases: immunotherapy and genetic modification. While immunotherapy serves to destroy tumor cells by activating the patient's immune system, genetic modification allows for individualization of treatment at the molecular and genetic levels. Studies show the effectiveness, safety, and clinical significance of innovative strategies. The article highlights the future development prospects of innovative treatment methods and their role in oncological practice.

Keywords: Oncological diseases, innovative treatment, immunotherapy, genetic modification, CAR-T cells, monoclonal antibodies, tumor cells, molecular therapy, clinical outcomes, individualized treatment.

Oncological diseases are recognized today as one of the most serious and complex problems in the global healthcare system. Their high morbidity and mortality rates make the development of effective treatment strategies urgent in global medicine. Traditional treatment methods, including surgery, chemotherapy and radiotherapy, while improving the quality of life of patients in many cases, in some cases limit the possibility of achieving complete remission and are not sufficiently effective in reducing the risk of relapse. Therefore, innovative approaches to the treatment of oncological diseases - immunotherapy and genetic modification - are gaining great importance in scientific and clinical practice.

Immunotherapy is a treatment method that allows you to identify and destroy tumor cells by activating or restoring the patient's immune system. This strategy not only enhances the natural defense mechanisms of the immune system, but also creates the possibility of targeted therapy by identifying molecular markers of tumor cells. Strategies such as monoclonal antibodies, chimeric antigen receptor T-cells (CAR-T) and immunosuppression inhibitors are highly effective in combating the disease and bring positive changes in clinical outcomes.

In addition, genetic modification allows you to individualize and increase the effectiveness of treatment by changing the molecular and genetic composition of tumor cells. This approach serves to provide therapy tailored to the patient's genetic profile and tumor molecular characteristics, and also helps to reduce the development of drug resistance.

The article analyzes in detail innovative treatment approaches in oncological diseases, their molecular basis, clinical practice, safety and efficacy aspects. At the same time, the future development prospects of immunotherapy and genetic modification

strategies and the role of them in improving patient health are also considered. These approaches not only increase the effectiveness of individualized treatment, but also contribute to the sustainable development of oncological practice.

Innovative treatment approaches in oncological diseases — immunotherapy and genetic modification — allow to significantly improve clinical outcomes and improve the quality of life of patients. Immunotherapy serves to identify and destroy tumor cells by activating the patient's immune system, which provides high efficiency as an adjunct to traditional treatment methods. Strategies such as monoclonal antibodies, CAR-T cells, and immunosuppression inhibitors help to implement an individualized approach to fighting the disease.

Genetic modification, on the other hand, increases the effectiveness of therapy by changing the molecular and genetic characteristics of tumor cells and reduces the development of drug resistance. This approach creates the possibility of individualized treatment tailored to the patient's genetic profile and tumor molecular characteristics.

Studies show that these innovative strategies are aimed at increasing remission rates, reducing the risk of relapse, and improving the quality of life of patients. At the same time, their use requires safety, molecular adaptability, and clinical monitoring.

In conclusion, immunotherapy and genetic modification are the main future directions in the treatment of oncological diseases, which allow for an individualized approach, high efficiency, and sustainable results. These innovative methods are of great importance in the development of oncological practice and improving patient health. At the same time, they create a safe and effective treatment strategy for patients, combined with clinical research and advanced technologies.

REFERENCES:

1. Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480(7378), 480–489.
2. June, C. H., Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379, 64–73.
3. Couzin-Frankel, J. (2013). Breakthrough of the year 2013: Cancer immunotherapy. Science, 342(6165), 1432–1433.
4. Morrison, C. (2016). Gene therapy: CRISPR in cancer treatment. Nature Reviews Clinical Oncology, 13, 9–10.
5. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355.
6. Sadelain, M., Brentjens, R., & Riviere, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discovery, 3(4), 388–398.
7. Maus, M. V., & June, C. H. (2016). Making better chimeric antigen receptors for adoptive T-cell therapy. Clinical Cancer Research, 22(8), 1875–1884.